Form 4: Zimmer Biomet Director Reports Stock Transactions

Syed A. Jafry, a Director at Zimmer Biomet Holdings, Inc., reported transactions involving phantom stock units and restricted stock units.

Summary

• Syed A. Jafry, a Director at Zimmer Biomet Holdings, Inc. (ZBH), reported transactions on May 22, 2026.
• The transactions involved phantom stock units (PSUs) and restricted stock units (RSUs).
• Jafry acquired 875.35 PSUs at a settlement value of $85.68 each, bringing his total to 8,288.638 PSUs.
• He also acquired 1,517.274 RSUs, with his total RSU holdings at 9,098.
• The PSUs are part of the Deferred Compensation Plan for Non-Employee Directors and will be settled in common stock within sixty days of service cessation.
• The RSUs are immediately vested but subject to mandatory deferral until the later of director termination or three years after the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine equity transactions by a director and does not contain new financial performance data or strategic shifts.

Positives

• Director Jafry's holdings in both phantom stock units and restricted stock units indicate continued equity-based compensation and alignment with the company.
• The immediate vesting of RSUs suggests a reward for past service or a commitment incentive.

Negatives

• The mandatory deferral period for RSUs means that a portion of Jafry's compensation is not immediately accessible, potentially limiting liquidity.

Risks

• The value of phantom stock units and restricted stock units is tied to the performance of Zimmer Biomet Holdings, Inc. common stock, exposing the reporting person to market risk.
• Changes in company policy or regulatory requirements could impact the terms or settlement of these equity awards.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions related to equity awards.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for directors and officers to report changes in their beneficial ownership of company stock. This filing indicates ongoing equity compensation practices at Zimmer Biomet Holdings, Inc., which is typical within the medical device industry.

Stakeholder Impact

• Shareholders: The transactions reflect standard director compensation practices and do not immediately indicate a change in ownership structure that would significantly impact share price.
• Employees: The filing is primarily relevant to executive compensation and governance, with no direct impact on general employees.
• Management: The filing details equity awards for a director, aligning their interests with the company's performance.

Next Steps

• Phantom stock units to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• Restricted Stock Units are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or the date that is three years after the grant date.

Key Dates

Keywords

Zimmer Biomet Holdings, ZBH, Form 4, Director, Syed A. Jafry, Phantom Stock Units, Restricted Stock Units, Equity Compensation, SEC Filing, Beneficial Ownership